AssemblyBio_logo_RGB.png
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023 08:00 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023 08:00 ET | Assembly Biosciences, Inc.
-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus development candidate -- -- Five posters accepted...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019
April 09, 2019 08:00 ET | VBI Vaccines, Inc.
Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccineIn all three studies, seroprotection rates of more than 98%...
Galectin Therapeutics, Inc. Logo
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
May 03, 2017 08:30 ET | Galectin Therapeutics
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver...
galectin.jpg
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
April 18, 2017 08:00 ET | Galectin Therapeutics
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN),...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
April 13, 2016 07:00 ET | Assembly Biosciences, Inc.
—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties— —Planning to Start Phase 1...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
March 30, 2016 07:30 ET | Assembly Biosciences, Inc.
BARCELONA, Spain and NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for...
OnCore Biopharma, Inc.
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
September 09, 2014 03:00 ET | OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018 NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...